John M. Schallenkamp MD MBA, MHQS
Associate Professor of Radiation Oncology
Join to view full profile
Cheyenne Regional Medical Center – West Campus214 E 23rd StCheyenne, WY 82001
Phone+1 307-672-1000
Fax+1 307-675-3639
Dr. Schallenkamp is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Radiation Oncology, 2001 - 2005
Aurora Health CareInternship, Transitional Year, 2000 - 2001
Medical College of WisconsinClass of 2000
Certifications & Licensure
CO State Medical License 2025 - 2027
MT State Medical License 2005 - 2027
WY State Medical License 2005 - 2027
MN State Medical License 2001 - 2005
WI State Medical License 2004 - 2005
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification HealthSentry, Cerner Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification P2 Sentinel, Cerner Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2016-2017
Clinical Trials
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Start of enrollment: 2018 Oct 26
- Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations Start of enrollment: 2018 Dec 10
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
Publications & Presentations
PubMed
- 21 citationsPhase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, Carl M Gay, Lauren A Byers
Journal of Thoracic Oncology. 2025-03-01 - 12 citationsSWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J Wilkinson, Emily M Whitman-Purves
Clinical Cancer Research. 2024-12-16 - First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinic...Richard K. Valicenti, Stephanie L. Pugh, Edouard J. Trabulsi, Oliver Sartor, Eric C. Ko
International Journal of Radiation Oncology, Biology, Physics. 2018-03-01
Press Mentions
Billings Clinic Fires CEOMay 21st, 2019
SWOG Reports Results in Gynecologic Cancer Immunotherapy TrialJanuary 20th, 1970
Grant Support
- Montana Cancer Consortium: An Inclusive and Collaborative Approach to Clinical Trial Accrual and Cancer Care Delivery Research across Montana, Idaho and WyomingMONTANA CANCER CONSORTIUM2025–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
